Skip to main content
    V

    Vaxcyte Inc (PCVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $61.61
    -1.76 (-2.78%)

    Market Cap: $10.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Vaxcyte Inc (PCVX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Vaxcyte reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$766.63M, operating cash flow was -$655.58M and free cash flow was -$669.29M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$297.06M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $923.67M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Research and development$794.31M$476.64M$332.34M$169.45M$78.41M$73.56M$45.61M$30.14M$12.79M
    Operating income-$923.67M-$569.55M-$468.04M-$232.26M-$103.67M-$89.58M-$54.15M-$35.53M-$17.83M
    Net income-$766.63M-$463.93M-$402.27M-$223.49M-$100.08M-$89.22M-$50.27M-$29.48M-$17.24M
    EBITDA-$875.92MN/AN/A-$223.33M-$95.55M-$88.05M-$49.18M-$29.28M-$17.21M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$14.45M
    Gross profit$0$0$0$4.99M$0$0$0N/A$0$0$0$11.50M
    Operating income-$308.27M-$302.78M-$345.85M-$274.28M-$242.38M-$226.22M-$180.79M-$162.17M-$139.92M-$152.98M-$114.47M-$196.68M
    Net income-$297.06M-$284.30M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M-$103.12M-$128.70M-$95.02M-$180.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $6.12M by $167.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$3.00B$3.51B$1.41B$1.01B$324.34M$392.83M$65.70M$70.80M$39.63M
    Current assets$1.63B$1.79B$1.10B$942.55M$256.35M$389.00M$61.72M$66.67M$36.35M
    Cash and equivalents$173.96M$387.88M$397.45M$834.66M$68.98M$386.20M$58.98M$66.09M$36.14M
    Total liabilities$317.21M$205.50M$167.45M$52.56M$40.32M$46.98M$11.76M$128.53M$8.69M
    Short-term debt$6.12M$5.89M$7.11M$5.91M$5.28MN/A$161.00K$297.00K$283.00K
    Long-term debtN/AN/AN/AN/AN/AN/A$450.00K$3.65M$3.76M
    Shareholder equity$2.69B$3.31B$1.24B$953.61M$284.02M$345.84M-$106.37M-$57.73M$30.94M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.99B$3.14B$3.35B$3.05B$3.17B$3.31B$3.38B$3.51B$3.56B$2.09B$2.09B$1.41B
    Total liabilities$499.92M$380.21M$352.29M$360.45M$278.72M$234.03M$178.08M$205.50M$142.11M$101.14M$107.32M$167.45M
    Cash and equivalents$125.47M$183.19M$260.84M$173.96M$281.08M$306.74M$346.85M$387.88M$1.05B$518.67M$611.51M$397.45M
    Shareholder equity$2.49B$2.76B$3.00B$2.69B$2.89B$3.07B$3.20B$3.31B$3.42B$1.99B$1.98B$1.24B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$655.58M-$452.63M-$296.79M-$170.60M-$121.39M-$46.63M-$47.15M-$30.47M-$14.96K
    Capital expenditures$13.71M$22.43M$16.06M$5.84M$6.55M$1.16M$1.20M$1.77M$1.22K
    Free cash flow-$669.29M-$475.05M-$312.85M-$176.44M-$127.95M-$47.78M-$48.34M-$32.24M-$16.18K
    Dividends paidN/AN/AN/AN/AN/A$374.00KN/AN/AN/A
    Investing cash flow$437.35M-$2.01B-$773.31M$74.58M-$212.31M-$1.10M-$1.20M-$1.77M-$1.12K
    Financing cash flow$2.01M$2.45B$639.81M$861.55M$17.80M$374.87M$41.57M$62.19M$43.86K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$224.08M-$232.47M-$280.63M-$224.83M-$143.31M-$121.17M-$166.27M-$111.40M-$60.71M-$121.39M-$159.12M-$128.81M
    Capital expenditures$3.33M$4.32M$2.11M$2.65M$3.82M$1.81M$5.42M$4.02M$4.95M$7.78M$5.68M$5.25M
    Free cash flow-$227.42M-$236.79M-$282.73M-$227.49M-$147.13M-$122.98M-$171.70M-$115.42M-$65.66M-$129.18M-$164.80M-$134.06M
    Last 12 quarters

    Frequently Asked Questions About PCVX

    What is Vaxcyte's annual revenue?

    Vaxcyte reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Vaxcyte profitable?

    No. Vaxcyte reported net income of -$766.63M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PCVX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$655.58M minus capital expenditures of $13.71M produced free cash flow of -$669.29M.

    How much debt does Vaxcyte have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $6.12M and cash and equivalents of $173.96M.